Expertise in
18
conditions

Dr. Carlos R. Bachier

Hematology
Methodist Hospital
7700 Floyd Curl Dr, 
San Antonio, TX 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
35 Years of Experience
Expertise in
18
conditions
Methodist Hospital
7700 Floyd Curl Dr, 
San Antonio, TX 

Overview

Carlos Bachier is a Hematologist practicing medicine in San Antonio, Texas. He has been practicing medicine for over 35 years.

Dr. Bachier is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Graft Versus Host Disease (GvHD), Acute Myeloid Leukemia (AML), Chronic Graft Versus Host Disease (cGvHD), Bone Marrow Transplant, and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 24 peer reviewed articles and participating in 12 clinical trials. Dr. Bachier is currently accepting new patients.

Specialties

Hematology

Licenses

Internal Medicine in PR

Hospital Affiliations

Methodist Hospital
Auxilio Mutuo Hospital

Languages Spoken

English
Spanish

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Community First Health Plans
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
First Medical Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medical Card System
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
  • PPO
MMM Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Plan De Salud Menonita
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 6 Less Insurance Carriers -

Locations

Methodist Hospital
7700 Floyd Curl Dr, San Antonio, TX 78229

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
Enrollment Status: Recruiting
Publish Date: July 06, 2026
Intervention Type: Drug
GRAVITAS-309: A Phase 2/3 Study of Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
GRAVITAS-309: A Phase 2/3 Study of Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
Enrollment Status: Terminated
Publish Date: October 20, 2025
Intervention Type: Drug
Study Drugs: Itacitinib, Methylprednisolone, Prednisone
Study Phase: Phase 2/Phase 3
A Single Arm, Open-label, Multi-centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO3, a CAR T Cell Treatment Targeting CD19 and CD22 With Anti Programmed Cell Death Protein 1 (PD1) Antibody in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma
A Single Arm, Open-label, Multi-centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO3, a CAR T Cell Treatment Targeting CD19 and CD22 With Anti Programmed Cell Death Protein 1 (PD1) Antibody in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma
Enrollment Status: Terminated
Publish Date: July 14, 2025
Intervention Type: Biological
Study Drugs: AUTO3, cyclophosphamide, fludarabine, pembrolizumab
Study Phase: Phase 1/Phase 2
A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting
A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting
Enrollment Status: Completed
Publish Date: February 27, 2025
Intervention Type: Biological
Study Drug: lisocabtagene maraleucel
Study Phase: Phase 2
A Phase 1 Study of NKX101, an Activating Chimeric Receptor Natural Killer Cell Therapy, in Subjects With Hematological Malignancies or Dysplasias
A Phase 1 Study of NKX101, an Activating Chimeric Receptor Natural Killer Cell Therapy, in Subjects With Hematological Malignancies or Dysplasias
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Biological
Study Drug: Allogeneic NKG2D-Targeted CAR-Natural Killer T Cells
Study Phase: Phase 1
A Phase 1, Open-label, Dose Escalating Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the Combination of CLBR001 and SWI019 in Patients With Relapsed/Refractory B-cell Malignancies
A Phase 1, Open-label, Dose Escalating Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the Combination of CLBR001 and SWI019 in Patients With Relapsed/Refractory B-cell Malignancies
Enrollment Status: Completed
Publish Date: August 20, 2024
Intervention Type: Combination product
Study Drugs: CLBR001 CAR-T Cells, SWI019
Study Phase: Phase 1
A Phase II Single Arm Study of Nivolumab as Maintenance Therapy After Autologous Stem Cell Transplantation in Patients With Hodgkin Lymphoma at Risk of Relapse or Progression
A Phase II Single Arm Study of Nivolumab as Maintenance Therapy After Autologous Stem Cell Transplantation in Patients With Hodgkin Lymphoma at Risk of Relapse or Progression
Enrollment Status: Completed
Publish Date: December 05, 2023
Intervention Type: Drug
Study Drug: Nivolumab
Study Phase: Phase 2
A Randomized Phase II/III Study of αβ T Cell-Depleted, Related, Haploidentical Hematopoietic Stem Cell Transplant (Haplo-HSCT) Plus Rivogenlecleucel vs. Haplo-HSCT Plus Post-Transplant Cyclophosphamide (PTCy) in Patients With AML or MDS
A Randomized Phase II/III Study of αβ T Cell-Depleted, Related, Haploidentical Hematopoietic Stem Cell Transplant (Haplo-HSCT) Plus Rivogenlecleucel vs. Haplo-HSCT Plus Post-Transplant Cyclophosphamide (PTCy) in Patients With AML or MDS
Enrollment Status: Terminated
Publish Date: September 29, 2023
Intervention Type: Biological, Drug, Procedure
Study Phase: Phase 2/Phase 3
Ph 1 Study of Escalating Single & Multiple Doses of Mana 312 (Multi Tumor-Associated Antigen T Cells) Administered to Adult Subjects With Acute Myeloid Leukemia or Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplant
Ph 1 Study of Escalating Single & Multiple Doses of Mana 312 (Multi Tumor-Associated Antigen T Cells) Administered to Adult Subjects With Acute Myeloid Leukemia or Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplant
Enrollment Status: Terminated
Publish Date: June 18, 2023
Intervention Type: Biological
Study Drug: Mana 312
Study Phase: Phase 1
A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients
A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients
Enrollment Status: Completed
Publish Date: March 03, 2023
Intervention Type: Drug, Other
Study Phase: Phase 3
View 9 Less Clinical Trials

24 Total Publications

Safety and efficacy of allogeneic CD19-directed CAR-T therapy CTX110 in relapsed/refractory B-cell non-Hodgkin lymphoma.
Safety and efficacy of allogeneic CD19-directed CAR-T therapy CTX110 in relapsed/refractory B-cell non-Hodgkin lymphoma.
Journal: Blood advances
Published: February 17, 2026
Similar Doctors
Expertise in
8
conditions
Expertise in
8
conditions
Referral may be required

University Of Texas Health Science Center At San Antonio

7979 Wurzbach Rd, 
San Antonio, TX 
 (0.6 miles away)
210-450-1406
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Robyn Scherber is a Hematologist practicing medicine in San Antonio, Texas. Dr. Scherber is highly rated in 8 conditions, according to our data. Her clinical expertise encompasses Myeloproliferative Neoplasms (MPN), Myelofibrosis, Polycythemia Vera, Essential Thrombocythemia, and Bone Marrow Transplant. Dr. Scherber is currently accepting new patients.

Expertise in
16
conditions
Dr. Ildefonso I. Rivera
Hematology | Oncology
Expertise in
16
conditions
Dr. Ildefonso I. Rivera
Hematology | Oncology
Referral may be required

Office

2829 Babcock Rd Ste 300, 
San Antonio, TX 
 (0.5 miles away)
210-580-9500
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Ildefonso Rivera is a Hematologist and an Oncologist practicing medicine in San Antonio, Texas. Dr. Rivera is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Gastric Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), and Follicular Lymphoma. Dr. Rivera is currently accepting new patients.

Expertise in
13
conditions
Expertise in
13
conditions
Referral may be required

Methodist Physicians Texas Transplant Specialists - Adult Blood Marrow Transplant

4450 Medical Dr Fl 1, 
San Antonio, TX 
 (0.5 miles away)
Languages Spoken:
English, Farsi
See accepted insurances
Accepting New Patients

Nosha Farhadfar is a Hematologist practicing medicine in San Antonio, Texas. Dr. Farhadfar is highly rated in 13 conditions, according to our data. Her clinical expertise encompasses Graft Versus Host Disease (GvHD), Chronic Graft Versus Host Disease (cGvHD), Acute Myeloid Leukemia (AML), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Farhadfar is currently accepting new patients.

Frequently Asked Questions about Dr. Carlos R. Bachier

How do I make an appointment with Dr. Carlos R. Bachier?

You can book an appointment with Dr. Carlos R. Bachier by calling their office at 210-575-3817. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Carlos R. Bachier a top-rated expert for Graft Versus Host Disease (GvHD)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Carlos R. Bachier is classified as an Distinguished expert for Graft Versus Host Disease (GvHD), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Carlos R. Bachier specialize in?

While Dr. Carlos R. Bachier is a Hematology, they have specific expertise in Graft Versus Host Disease (GvHD), Acute Myeloid Leukemia (AML), and Chronic Graft Versus Host Disease (cGvHD). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Carlos R. Bachier participate in research or clinical trials?

Yes. Dr. Carlos R. Bachier has published 24 articles and abstracts on conditions like Graft Versus Host Disease (GvHD). You can view a list of Dr. Carlos R. Bachier's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Carlos R. Bachier accept my insurance?

Dr. Carlos R. Bachier accepts most major insurance plans, including Blue Cross Blue Shield and Community First Health Plans. We recommend calling the office directly at 210-575-3817 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bachier's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 11 Advanced Conditions
    View All 32 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile